Nautilus Biotechnology EPS NAUT
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Sep 30, 2026
- −$0.46
- Latest quarter, Q3 FY26
- −$0.12
- Fiscal year 2025
- −$0.47
Nautilus Biotechnology's earnings per share was −$0.46 over the twelve months to Sep 30, 2026.
In its latest quarter, Q3 FY26, it was −$0.12.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.47 | n/a |
| FY2024 | −$0.56 | n/a |
| FY2023 | −$0.52 | n/a |
| FY2022 | −$0.47 | n/a |
| FY2021 | −$0.69 | n/a |
| FY2020 | −$0.53 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.12 | n/a | −$0.46 | |
| Q2 FY26 | −$0.11 | n/a | −$0.45 | |
| Q1 FY26 | −$0.12 | n/a | −$0.46 | |
| Q4 FY25 | −$0.11 | n/a | −$0.47 | |
| Q3 FY25 | −$0.11 | n/a | −$0.50 | |
| Q2 FY25 | −$0.12 | n/a | −$0.52 | |
| Q1 FY25 | −$0.13 | n/a | −$0.54 | |
| Q4 FY24 | −$0.14 | n/a | −$0.56 | |
| Q3 FY24 | −$0.13 | n/a | −$0.56 | |
| Q2 FY24 | −$0.14 | n/a | −$0.56 | |
| Q1 FY24 | −$0.15 | n/a | −$0.55 | |
| Q4 FY23 | −$0.14 | n/a | −$0.52 |
Against its peers
Companies in Healthcare nearest Nautilus Biotechnology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NAUTNautilus Biotechnology | −$0.46 | |
| CYHCommunity Health Systems | $0.26 | −89% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| VMDViemed Healthcare | $0.36 | +6% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| ELMDElectromed | $1.31 | +56% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| CRMDCorMedix | $2.13 | +184% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| PDEXPro DEX | $3.63 | +8% a year |
| Peer median | $1.16 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Nautilus Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.